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http://dx.doi.org/10.1016/j.ccr.2013.06.017SUMMARYAmong the cytokines linked to inflammation-associated cancer, interleukin (IL)-6 drives many of the cancer
‘‘hallmarks’’ through downstream activation of the gp130/STAT3 signaling pathway. However, we show that
the related cytokine IL-11 has a stronger correlation with elevated STAT3 activation in human gastrointestinal
cancers. Using genetic mouse models, we reveal that IL-11 has a more prominent role compared to IL-6 dur-
ing the progression of sporadic and inflammation-associated colon and gastric cancers. Accordingly, in
thesemodels and in human tumor cell line xenograft models, pharmacologic inhibition of IL-11 signaling alle-
viated STAT3 activation, suppressed tumor cell proliferation, and reduced the invasive capacity and growth
of tumors. Our results identify IL-11 signaling as a potential therapeutic target for the treatment of gastroin-
testinal cancers.INTRODUCTION
The onset and progression of cancer is facilitated by complex
interactions between neoplastic cells and the heterogeneous
stromal cell populations that are present in the tumor microenvi-
ronment (Egeblad et al., 2010; Hanahan and Coussens, 2012).
While this is best documented for gastrointestinal (GI) cancersSignificance
STAT3 activation is linked to poor survival in patients with c
Accordingly, inhibitors of IL-6 signaling are in clinical trials for a
mation-associated and sporadic gastrointestinal cancers, we h
potent driver of tumor progression than IL-6. Pharmacologic in
cancer and human tumor cell line xenografts inhibited the inva
Importantly, IL-11 inhibition had no impact on hematopoiesis,
data provide support for the clinical development of IL-11 signassociatedwith persistent inflammation, the tumormicroenviron-
ment can also promote the growth of sporadic cancers arising
from tumor intrinsic oncogenic mutations (Grivennikov et al.,
2012). Studies utilizing knockout mice have begun to unravel the
complex interplay between the neoplastic and stromal cells and
have highlighted pivotal roles for inflammatory cytokines. In turn,
thesecytokinescollectively promote cancer hallmark capabilities,ancer and is thought to arise primarily from elevated IL-6.
number of epithelial cancers. Usingmousemodels of inflam-
ave discovered that the IL-11/STAT3 signaling axis is amore
hibition of IL-11/STAT3 in mouse models of gastrointestinal
sive capacity of neoplastic cells and reduced tumor growth.
an undesirable side effect of systemic STAT3 inhibition. Our
aling antagonists for the treatment of epithelial cancers.
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IL-11 Is a Therapeutic Target in GI Cancerincludingproliferation, angiogenesis, andmetastasis,while simul-
taneously inducing resistance of neoplastic cells to death stimuli
and immune destruction (Hanahan and Weinberg, 2011).
The interleukin (IL)-6 family of cytokines is defined by the
shared use of the gp130 receptor b-subunit. Included within
this family are IL-6, recognized for its role as a systemic acute
phasemediator (Heinrich et al., 1990), and IL-11,which promotes
platelet production (Teramura et al., 1992).More recently, both of
these cytokines have been linked to the development of epithelial
cancers (Matsuo et al., 2003; Nakayama et al., 2007). While acti-
vatedmyeloid cells are thought to producemost of the IL-6 in the
tumor microenvironment, autocrine IL-6 signaling in neoplastic
epithelial cells has also recently been documented (Gao et al.,
2007; Grivennikov et al., 2009). IL-11 on the other hand is pro-
duced by cancer-associated fibroblasts (CAFs) in patients with
colorectal cancer (CRC) and bymyeloid cells and can be upregu-
lated in cancer cells as part of an autocrine signaling loop (Calon
et al., 2012; Ernst et al., 2008; Schwitalla et al., 2013; Shin et al.,
2012). Although the engagement of the gp130 receptor by either
IL-6 or IL-11 induces transient activation of Janus kinases (JAK)
and the latent transcription factor STAT3, tissue responses are
dependent on either the presence of soluble IL-6 receptor (R)
or expression of the membrane-associated IL-6Ra and IL-11Ra
receptors (Becker et al., 2004; Heinrich et al., 1998).
Excessive STAT3 activation is a feature of the majority of solid
cancers and is frequently associated with elevated cytokine
expression, including IL-6 and IL-11 (Ernst et al., 2008; Grivenni-
kov et al., 2009). However, some epithelial malignancies are also
associatedwith activating somaticmutations in thegenesencod-
ing STAT3, gp130, and associated JAK1/2, as well as epigenetic
silencing of the SOCS3 gene, which encodes a critical negative
regulator for gp130 cytokine signaling (Casanova et al., 2012;
He et al., 2003; Rebouissou et al., 2009). In GI cancers, excessive
STAT3 activation is also linked to tumor invasion and nodal
metastasis and predicts poor patient survival (Deng et al., 2010;
Kimetal., 2009;Morikawaetal., 2011).Wehavepreviously shown
that epithelial STAT3 activation in mice promotes inflammation-
associated gastric cancer (GC) and colitis-associated colorectal
cancer (CAC) (Bollrath et al., 2009; Ernst et al., 2008). Further-
more, genetic reduction of STAT3 expression diminished tumor
burden in these models, and suggested that pharmacologic tar-
geting of the gp130/STAT3 signaling pathway may confer signif-
icant therapeutic benefits in the treatment of thesemalignancies.
The concept of combating tumor progression through phar-
macologic inhibition of growth-promoting cytokines is emerging
as a therapeutic opportunity that bypasses the difficulties of tar-
geting intracellular signalingmolecules and transcription factors.
To date, much focus has been placed on antagonizing the activ-
ity of IL-6, with clinical trials for ovarian, renal, prostate, and
breast cancers underway (Guo et al., 2012; Puchalski et al.,
2010). Here, we investigate the role of the related cytokine IL-
11 in GI tumorigenesis.
RESULTS
Increased IL-11 Expression in Human GI Cancers Is
Associated with Excessive STAT3 Activation
Although elevated IL-6 expression is linked to excessive
STAT3 activation associated with poor survival in patients with258 Cancer Cell 24, 257–271, August 12, 2013 ª2013 Elsevier Inc.CRC, less is known about the role of IL-11 in these cancers
(Esfandi et al., 2006; Morikawa et al., 2011). We therefore
compared the expression of IL6 and IL11 in a panel of 14 primary
CRC samples (Figure 1A) and in 16 primary human GC samples
(Figure S1A available online). We found that both cytokines were
consistently elevated in tumor tissue compared to unaffected GI
tissues from the same patients. To examine the relationship be-
tween epithelial STAT3 activation and the expression of inflam-
matory cytokines associated with tumorigenesis, we assessed
pTyr-STAT3 staining as a marker of activated STAT3, in addi-
tional CRC samples, and found that only IL11mRNA expression
significantly correlated with high epithelial STAT3 activation (Fig-
ures 1B and S1B). Within this high STAT3 patient cohort, we
found no correlation between IL6 and IL11 expression (not
shown). Because we consistently observed heterogeneous
STAT3 activation within tumor samples, we characterized the
location of pTyr-STAT3 positive cells within a panel of 59
resected primary CRC samples. We observed strong pTyr-
STAT3 staining in the tumor core in 39% (23 of 59) of samples.
When we scored invasive regions of these tumors separately,
we found strong pTyr-STAT3 staining in 61% (36 of the 59; Fig-
ure 1C) of samples, suggesting a potent trigger for STAT3 activa-
tion near the invasive front. Similarly, in a panel of GC samples,
we observed high levels of epithelial STAT3 activation in 26%
(33 of 125) of the specimens (Figure S1C). Collectively, these ob-
servations suggest that IL-11-mediated STAT3 activation may
be associated with epithelial tumorigenesis and invasion of
neoplastic cells into the submucosa.
IL-11 Signaling Is a Dominant Driver of Inflammation-
Associated Colon Cancer in Mice
To compare the role of IL-6 and IL-11 during CRC, we induced
CAC in mice. In the CAC model (Figure 2A), a single injection
of the alkylating mutagen azoxymethane (AOM) leads to spo-
radic induction of a number of mutations, including mis-sense
mutations in Ctnnb1 in intestinal epithelial cells, resulting in sta-
bilization of the corresponding b-catenin protein and aberrant
activation of the Wnt-signaling pathway (Neufert et al., 2007;
Tanaka et al., 2005). Subsequent repetitive administration of
the luminal irritant dextran sulfate sodium (DSS) promotes
‘‘flares’’ of inflammation, akin to those observed in chronic ulcer-
ative colitis, which augment colonic tumor development in mice
(Wirtz et al., 2007). Similar to our observation in human CRC, we
detected increased IL-11 and pTyr-STAT3 protein levels in the
distal colonic tumors of wild-type (WT) mice on day 72 of the
CAC protocol (Figure 2B). Because the progression of CAC-
induced colonic neoplasias is mediated by STAT3 (Bollrath
et al., 2009; Grivennikov et al., 2009), we compared the require-
ment for the STAT3 activating cytokines IL-6 and IL-11 during
this process. Using serial endoscopy, we detected macroscopic
tumors in WT and Il6KO mice by day 47, whereas tumor onset
was substantially delayed in Il11ra1KO and Il6KO;Il11ra1KO com-
pound mutant mice (Figure 2C). Although the absence of IL-6
signaling resulted in a lower frequency of colonic adenomas in
Il6KO mice compared to WT mice (Grivennikov et al., 2009), tu-
mors were almost completely absent in the colons of Il11ra1KO
mice at autopsy, irrespective of the presence of IL-6 (Figures
2C–2E). Consistent with a dominant role for IL-11-mediated
STAT3 activation in tumor formation we observed a reduction
Figure 1. Elevated IL11 Expression in Hu-
man CRC Is Associated with Excessive
STAT3 Activation
(A) IL6 and IL11 mRNA expression in 14 individual
human CRC samples. Data were normalized to
GAPDH expression and are shown as fold change
compared to unaffected colon tissue from the
same patients.
(B) STAT3 activation in 46 human CRC samples
was determined by immunohistochemistry for
pTyr-STAT3 to classify samples with low (24 sam-
ples) or high (22 samples) STAT3 activation fol-
lowed by analysis for IL6 and IL11 mRNA expres-
sion. Data were normalized to GAPDH expression
and are shown as mean ± SEM (*p < 0.05).
(C) Representative pTyr-STAT3 immunohisto-
chemistry depicting STAT3 activation in the core
region (oval) or invasive front (rectangle) of repre-
sentative human CRC samples. The bottom row
depicts higher magnifications of the boxed areas.
Scale bars: 3 mm (top row); 300 mm (bottom row).
See also Figure S1.
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Il11ra1KO mice following a single injection of AOM and one cycle
of DSS (Figure S2A). Similarly, distal colonic tumors from
Il11ra1KO and Il6KO;Il11ra1KO mice showed reduced levels of
pTyr-STAT3 and reduced expression of the downstream target
protein BCL-2, compared to WT and Il6KO mice (Figure 2F).
To further validate the requirement for IL-11 signaling in the
CAC model, we utilized homozygous gp130F/F mutant mice
that expressed gp130(Y757F) (Tebbutt et al., 2002).Cancer Cell 24, 257–271gp130(Y757F) cannot interact with
gp130’s negative regulator SOCS3, lead-
ing to enhanced IL-6 family cytokine-
mediated STAT3 activation (Figure S2B).
First, we confirmed that IL-11 expression
was elevated in the CAC tumors of
gp130F/F mice (Figure S2C). We next
inhibited IL-11 or IL-6 signaling geneti-
cally in gp130F/F mice and revealed a
dominant role for IL-11 driven STAT3 acti-
vation in promoting CAC-induced tumor-
igenesis (Figures S2D–S2G). Moreover,
the reduction in tumor burden observed
in Il11ra1KO and gp130F/F;Il11ra1KO mice
coincided with a reduction in the submu-
cosal inflammation compared to tumor-
bearing WT and gp130F/F mice (Figures
2E and S2F). Collectively, these observa-
tions establish IL-11 signaling as a driver
of inflammation-associated tumorigen-
esis that is more profound than that previ-
ously ascribed to IL-6.
Colonic Tumorigenesis Is Not
Dependent on IL-11-Responsive
Hematopoietic Cells
Physical disruption of the mucosal barrier
by DSS exposes innate immune cells ofthe submucosa to luminal antigens and provides a stimulus for
the production of pro-inflammatory cytokines that can fuel
epithelial tumor progression (Hanahan and Coussens, 2012).
To determine whether the tumor-promoting function of IL-11
was mediated by cells of hematopoietic origin, we generated
reciprocal bone marrow chimeras. Following complete engraft-
ment, recipient mice were subjected to only the first two DSS
cycles of the CAC protocol (Figure 2A) and were then monitored
by serial endoscopy. We found that tumor burden in lethally, August 12, 2013 ª2013 Elsevier Inc. 259
Figure 2. IL-11 Is the Dominant IL-6 Family Cytokine during CAC in Mice
(A) Schematic representation of the CACmodel. A single injection of AOM is followed by repeated administration of DSS provided ad libitum in the drinking water.
The formation of distal colonic tumors is then monitored by endoscopy at the indicated time points.
(B) Representative immunoblot analysis of distal colonic tumor (T) and adjacent nontumor (N) tissue fromWTmice collected on day 72 of the CACmodel. ERK1/2
was used as a loading control.
(C) Tumor burden of mice of the indicated genotypes was scored by endoscopy at day 47 and 72 of the CAC model; data are presented as mean ± SEM (nR 4
mice per cohort; **p < 0.01, ***p < 0.001).
(D) Colonic tumor burden from individual mice of the indicated genotypes at autopsy on day 72. Horizontal lines refer to mean values (nR 5 mice per cohort; *p <
0.05, **p < 0.01, ***p < 0.001).
(E) Representative endoscopy images (top row) of distal colonic tumors (arrowhead) on day 72 of the CAC model. Representative images of corresponding
hematoxylin and eosin stained (H&E) sections (bottom row) with regions of inflammatory cell infiltration (arrows) in the tumor microenvironment. Scale bars:
200 mm; inset: 130 mm.
(F) Representative immunoblot analysis of colonic tumors (T) and adjacent nontumor (N) tissues for pTyr-STAT3 and BCL-2 frommice of the indicated genotypes
collected on day 72 of the CAC model. ERK1/2 was used as a loading control.
See also Figure S2.
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marrow was comparable to that of their WT littermates reconsti-
tuted with WT bone marrow (Figures 3A and 3B). In contrast,
loss of IL-11 signaling in the nonhematopoietic cells of recipient
Il11ra1KO hosts rendered mice resistant to CAC. To examine
whether loss of IL-11 signaling altered the recruitment of im-
mune cells into the tumor microenvironment, we stained colons
for CD45-positive hematopoietic cells, F4/80-positive macro-
phages (Figures 3C and 3D), Gr1-positive neutrophils, and260 Cancer Cell 24, 257–271, August 12, 2013 ª2013 Elsevier Inc.CD3-positive lymphocytes (Figure S3A). This revealed that
tumor-associated submucosal immune cell infiltrates occurred
irrespective of the capacity of the hematopoietic cells to
respond to IL-11. Likewise, we observed that the expression
of many inflammatory cytokines in tumors and unaffected
colonic mucosa were not affected by the absence of IL-11-
responsive hematopoietic cells (Figure S3B). In contrast,
Il11ra1 ablation in the nonhematopoietic compartments of the
recipient hosts led to a reduction in submucosal inflammation
Figure 3. IL-11-Responsive Hematopoietic Cells Are Dispensable for Tumorigenesis
(A) Tumor burden of reciprocal WT and Il11ra1KO (KO) bone marrow chimeras was scored by endoscopy at day 47 and 72 of the CAC model and is depicted as
mean ± SEM (nR 4 mice per cohort; ***p < 0.001).
(B) Colonic tumor burden in individual reciprocal WT and Il11ra1KO (KO) bone marrow chimeras at autopsy on day 72 of the CAC model. Horizontal lines refer to
mean values (nR 3 mice per cohort; *p < 0.05, **p < 0.01, ***p < 0.001).
(C) Representative endoscopy images (top row) of distal colonic tumors (arrowhead) on day 72 of the CACmodel. Representative immunohistochemical staining
for the pan-hematopoietic marker CD45 (middle row) and the macrophage marker F4/80 (bottom row) on adjacent sections of distal colonic tumors frommice of
the indicated genotype. Arrows indicate submucosal cell infiltrates. The insets depict higher magnification areas. Scale bars: 200 mm; inset: 30 mm.
(D) Quantification of inflammatory cell infiltrates detected in the submucosa of the sections in (C). Scores are presented as mean ± SEM (nR 3 mice per cohort;
***p < 0.001).
See also Figure S3.
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IL-11 Is a Therapeutic Target in GI Cancer(Figures 3C and 3D) and associated Tnf expression, while the
expression of other inflammatory cytokines was not altered (Fig-
ure S3B). Our results suggest that tumorigenesis depends on IL-
11 signaling and correlates with the severity of inflammation and
that IL-11 mediates these effects through nonhematopoietic
cells.Sporadic Intestinal Tumorigenesis Requires IL-11
Signaling
The vast majority of sporadic human CRCs arise as a conse-
quence of somatic mutations in components of the Wnt/b-cate-
nin pathway in the absence of chronic inflammatory conditions.
To examine the role of cytokines that signal via gp130 receptorCancer Cell 24, 257–271, August 12, 2013 ª2013 Elsevier Inc. 261
Figure 4. Loss of IL-11/STAT3 Signaling De-
lays the Onset of Sporadic CRC in Mice
(A) Schematic representation of the sporadic CRC
model. The spontaneous formation of distal
colonic tumors in mice injected weekly with AOM
is monitored by endoscopy.
(B) Il6 and Il11 mRNA expression in distal colonic
tumor and adjacent nontumor tissue from
gp130F/F mice collected at week 16 of the spo-
radic CRCmodel. Data were normalized toGapdh
expression and are shown as mean relative
expression (2^dCT) ± SEM (nR 3mice per cohort;
*p < 0.05).
(C) Tumor burden of individual mice of the indi-
cated genotype was scored by endoscopy at the
indicated time and is presented as mean ± SEM
(nR 4mice per cohort; *p < 0.05, **p < 0.01, ***p <
0.001). yMoribund gp130F/F mice that were
euthanized by 18 weeks for ethical compliance.
(D) Representative endoscopy images (top row) of
distal colonic tumors (arrowhead) at weeks 18–20
of the sporadic CRC model. Representative im-
ages of H&E tissue sections (bottom row) with
regions of inflammatory cell infiltration (arrows) in
the tumor microenvironment. Scale bars: 200 mm.
(E) Colonic tumor burden in individual Apcmin/+
compound mutant mice at 150 days of age. Hori-
zontal lines refer to mean values (n R 9 mice per
cohort; *p < 0.05, **p < 0.01, ***p < 0.001).
(F) Representative images of H&E sections of the
distal small intestine from compound mutant
Apcmin/+ mice of the indicated genotypes. Scale
bars: 200 mm.
See also Figure S4.
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WT and gp130F/F mice repeatedly with AOM (Figure 4A).
Because the distal colonic tumors of gp130F/F mice showed
increased Il6 and Il11 expression compared to unaffected adja-
cent tissue (Figure 4B), we carried out serial endoscopy to
assess tumor progression in gp130F/F mice with impaired IL-6,
IL-11, or STAT3 signaling. In this model of the early stages of
sporadic CRC observed in humans, the colonic tumor latency
in gp130F/F mice was reduced to 20 weeks, compared to over
35 weeks in WT controls (Figure 4C). We consistently observed262 Cancer Cell 24, 257–271, August 12, 2013 ª2013 Elsevier Inc.reduced tumor burden in gp130F/F;
Il11ra1KO and gp130F/F;Stat3+/ mice,
compared to the gp130F/F mice (Figures
4C, 4D, and S4A). This coincided with
reduced expression of the STAT3 target
geneSocs3 in the remaining small tumors
of gp130F/F;Il11ra1KO mice (Figure S4B),
where we surmise that other cytokines
may account for the residual expression
of Socs3. Although pan-inflammatory
disease is reduced in gp130F/F;Il6KO
mice (Ernst et al., 2008) and associated
with prolonged survival compared with
their gp130F/F littermates, the colonic tu-
mor burden was comparable between
the two cohorts (Figures 4C and 4D).These observations are consistent with previous findings that
gastric tumorigenesis is not the cause of premature death in
the gp130F/F mice and collectively confirm a dominant role for
IL-11 signaling during sporadic CRC.
Given the dependency of AOM-induced tumorigenesis on
activating mutations in Ctnnb1, we next examined the cellular
distribution of b-catenin in neoplastic crypts. As expected,
we observed nuclear b-catenin staining, indicative of active
Wnt-signaling, in the cells of emerging tumors and the pro-
liferative intestinal stem cell region of crypts of gp130F/F and
Cancer Cell
IL-11 Is a Therapeutic Target in GI Cancergp130F/F;Il11ra1KO mice (Figure S4C). This was supported
by comparable expression of the Wnt-target genes Cd44,
Axin2, and Myc between mice of the different genotypes
and suggests that alteration of IL-11/STAT3 signaling does not
alter Wnt-signaling (Figure S4D). Although our AOM-only CRC
model lacks the flares of inflammation arising from DSS admin-
istration, limiting STAT3 signaling in gp130F/F;Il11ra1KO or
gp130F/F;Stat3+/ mice reduced tumor-associated submucosal
inflammation (Figure 4D) and expression of markers associated
with inflammation (Cox2, Tnf), invasion (Mmp9), and proliferation
(Ccnd1; Figure S4D).
Our observations suggest that interference with IL-11/STAT3
signaling may be able to limit Wnt/b-catenin-driven intestinal
tumorigenesis. To further validate this hypothesis, we next
employed the Apcmin/+ mouse model of familial adenomatous
polyposis syndrome, where spontaneous intestinal dysplasia
develops from loss of heterozygosity of the Apc gene (Su
et al., 1992). Reminiscent of our findings in the CAC and sporadic
CRC AOM-only models (Figures 2 and 4), we observed elevated
expression of Il6 and Il11 in Apcmin/+ tumors compared to adja-
cent unaffected tissue (Figures S4E and S4F). We confirmed
that genetic ablation of Il6 reduced tumor numbers and burden
(Baltgalvis et al., 2008), and show that tumorigenesis was even
further reduced in Apcmin/+;Il11ra1KO mice (Figures 4E and 4F).
Collectively, these results suggest that IL-11 signaling is required
for the development of intestinal tumors that share aberrant acti-
vation of the Wnt/b-catenin pathway as an underlying initiating
oncogenic event.
IL-11 Signaling Can Be Targeted Therapeutically
We reasoned that a reduction in GI tumor burden following par-
tial genetic inhibition of the IL-11 signaling pathway was required
to justify the development of therapeutics against this pathway.
To this end, we utilized gp130F/F mice as a validated model of
spontaneously arising intestinal-type GC. While the gastric
tumors that form in the distal antrum of gp130F/F mice have
abnormally elevated expression of both IL-6 and IL-11 (Fig-
ure S5A), the strict dependence of gastric tumor growth on IL-
11 signaling (Ernst et al., 2008) makes it an ideal model to test
anti-IL-11 therapies. We found that at all stages of gastric tumor
development, gp130F/F mice lacking one allele of Stat3 or Il11ra1
had consistently reduced tumor burden compared to their con-
trol gp130F/F littermates (Figures S5B and S5C). These results
suggest that partial inhibition of the IL-11/STAT3 signaling axis
is sufficient to cause a significant reduction in tumor burden.
To test the effects of an antagonist of IL-11 signaling in a
model of GI cancer, we systemically treated gp130F/F mice
with mIL-11 Mutein, a potent IL-11 signaling antagonist that
has a 20-fold higher affinity than IL-11 for binding to IL-11Ra
(Lee et al., 2008). We found that the IL-11 antagonist reduced
pTyr-STAT3 levels in the gastric tumors and adjacent hyper-
plastic antrum tissue (Figure 5A).We next explored the therapeu-
tic potential of prolonged systemicmIL-11Mutein administration
and found that regardless of the stage of disease, age, and sex of
the mice, mIL-11 Mutein treatment significantly reduced overall
tumor burden and gastric epithelial hyperplasia (Figures 5B–
5D). Successful treatment with different doses of themIL-11Mu-
tein for 4 weeks was not associated with weight loss (Figures
S5D and S5E) or changes in hematopoietic composition,including platelet counts (Figure S5F), and did not compromise
hemostasis (Figures S5G and S5H).
To explore whether mIL-11 Mutein conferred a transient or
a long-lasting therapeutic benefit, we randomly assigned
gp130F/F mice that were treated with mIL-11 Mutein for 4 weeks
to either a cohort for immediate analysis or a cohort for a 4-week
treatment-free follow-up period. We found that gastric tumor
burden in the follow-up cohort was increased compared to the
mIL-11 Mutein treatment-only cohort (Figures 5E–5G), suggest-
ing that continuous inhibition of IL-11 signaling is required to
block tumors.
To investigate the mechanism by which mIL-11 Mutein re-
duces tumor burden, we quantified the numbers of PCNA-posi-
tive proliferative and Apop-tag-positive apoptotic epithelial cells
in the gastric tumors (Figures 6A and S6A). The decrease in
PCNA-positive cells observed in mIL-11 Mutein-treated animals
coincided with reduced expression of the cell-cycle regulators
Cyclin D1, D2, and D3 (Figure 6B). Surprisingly, we found that
mIL-11 Mutein treatment was also associated with increased
expression of the pro-apoptotic protein BIM, rather than a reduc-
tion in the STAT3 target prosurvival protein BCL-2 (Figure 6C).
Moreover, mIL-11 Mutein treatment diminished submucosal
inflammation, reflected by the reduced infiltration of CD45-pos-
itive hematopoietic and F4/80-positive macrophage cells and
reduced expression of the inflammatory mediators KC and IL-
1b (Figures 6D, S6B, and S6C).
IL-6 and IL-11 Activate Similar Gene Expression
Signatures but Target Different Cells
Because both IL-6 and IL-11 are secreted by epithelial and
CD45-positive hematopoietic cells in the gastric tissue of
gp130F/F mice (Figures S6D and S6E), we performed microarray
analysis to explore the underlying mechanism for the require-
ment of IL-11 signaling for gastric tumor promotion. We
compared gene expression in gastric tumors of gp130F/F mice
following a single injection of recombinant human IL-6 or IL-11.
The gene expression profiles of the IL-6- and IL-11-treated sam-
ples were separately compared to the PBS-vehicle-treated con-
trol samples, resulting in two lists of responsive genes (Table S1).
Comparison of these lists revealed an extensive overlap of
responsive genes between the two cytokines (i.e., Socs3, Vegfa,
Pim3, Reg3b) with a notable bias for a more profound response
to IL-6 (Table S1; Figure S6F). As expected, functional classifica-
tion analysis showed that genes on either list belong to 13 com-
mon functional gene clusters (Figure S6G). However, we also
identified several genes that were specifically regulated by only
one of the two cytokines (Figure S6F). We found that some of
the IL-6-specific genes were associated with immune cells
(i.e., Dusp6, Junb, Cish/Socs1), while those specific for IL-11
were associated with epithelial activities (i.e., Spp1/Osteopon-
tin). The small difference in gene signatures associated with
different cellular functions suggested that IL-6 and IL-11 may
target different cell populations. To explore this possibility, we
adoptively transferred gp130F/F;Il11ra1KO bone marrow into
lethally irradiated gp130F/F mice with early gastric tumors. We
found that the tumor burden in these mice remained similar to
that of gp130F/F littermates reconstituted with gp130F/F bone
marrow (Figure 6E). Collectively, our data suggest that IL-6 and
IL-11 activate similar gene expression signatures, with gastricCancer Cell 24, 257–271, August 12, 2013 ª2013 Elsevier Inc. 263
Figure 5. Pharmacologic Inhibition of IL-11 Signaling Inhibits Gastric Tumorigenesis
(A) Representative immunoblot analysis for activated STAT3 (pTyr-STAT3) in gastric antral and tumor tissue from individual 12-week-old gp130F/F mice treated
with mIL-11 Mutein or a vehicle control on days 1, 3, and 5. ERK1/2 was used as a loading control.
(B) gp130F/F mice with established gastric tumors were treated withmIL-11Mutein or a vehicle control for 4 consecutive weeks. Treatment commenced at 8 (red),
12 (blue), or 20 weeks (green) of age.
(C) Total gastric tumor mass of individual control- and mIL-11 Mutein-treated gp130F/F mice of the treatment age group indicated in (B). Horizontal lines refer to
mean values (nR 5 mice per cohort; ***p < 0.001).
(D) Representative whole mounts of stomachs (left) and corresponding H&E longitudinal sections (right) from 16-week-old control and mIL-11 Mutein-treated
gp130F/F mice. Stomachs were opened along the greater curvature and pinned-out with the lumen facing the viewer (f = fundus, a = antrum). Scale bars: 6 mm
(whole mount); 500 mm (H&E).
(E–G) Sixteen-week-old gp130F/F mice were analyzed after 4 consecutive weeks of mIL-11 Mutein treatment or after an additional 4-week treatment-free follow-
up period. Representative whole mounts of stomachs of gp130F/F mice of the indicated treatment group (E); f, fundus; a, antrum; scale bar: 6mm. In eachmouse,
individual tumors were classified according to their size (F) and the combined mass of resected tumors was determined (G). Horizontal lines and histograms refer
to mean values (nR 8 per mice cohort; *p < 0.05, **p < 0.01, ***p < 0.001).
See also Figure S5.
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that may be biased toward IL-11 responsiveness.
mIL-11 Mutein Therapy Suppresses CAC Tumor
Progression
Having demonstrated that IL-11 signaling can be therapeutically
targeted in the gp130F/F model of spontaneous GC (Figure 5), we264 Cancer Cell 24, 257–271, August 12, 2013 ª2013 Elsevier Inc.next examined whether mIL-11 Mutein could confer a thera-
peutic benefit in the absence of predetermined mutations in
gp130F/F mice. Therefore, we treated WT mice with established
CAC tumors for 4 weeks with mIL-11 Mutein (Figure S7A). Serial
endoscopy revealed that mIL-11 Mutein treatment led to a cyto-
static effect on existing colonic tumors (Figure 7A), which was
confirmed at autopsy by a significant reduction in tumor
Figure 6. Mutein Treatment Reduces Tumor Cell Proliferation and Triggers Cell Death
(A) Representative immunohistochemical staining for proliferation (PCNA) and cell death (Apop-Tag) markers on adjacent gastric tumor sections from control-
and mIL-11 Mutein-treated gp130F/F mice at 12 weeks of age. Scale: 200 mm.
(B andC) Immunoblot analysis of gastric antral and tumor tissue from individual 12-week-old gp130F/Fmice treatedwithmIL-11Mutein or a vehicle control (Ctl) on
days 1, 3, and 5 and analyzed for the expression of cyclin (B) or apoptosis-related proteins (C). ERK1/2 was used as a loading control.
(D) Representative immunohistochemical stainings for the pan-hematopoietic marker CD45 and the macrophage marker F4/80 on adjacent gastric tumor
sections from control and mIL-11 Mutein-treated gp130F/F mice at 12 weeks of age. Scale bars: 200 mm.
(E) Total gastric tumor numbers (left) andmass (right) of gp130F/F bonemarrow chimeras at 14 weeks of age. Horizontal lines refer to mean values (nR 4mice per
cohort).
See also Figure S6 and Table S1.
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ures 7B and 7C). We also confirmed that mIL-11 Mutein signifi-
cantly alleviated CAC-induced tumor burden in gp130F/F mice
(Figures S7B and S7C). Importantly, we show that in gp130F/F
mice, mIL-11 Mutein treatment reduced neoplastic colonic
epithelial proliferation and increased apoptosis (Figures S7D
and S7E). Interestingly, gp130F/F mice display elevated colonictumor BCL-2 expression compared to WT mice (Figure 2F),
which was not altered following Mutein treatment (Figure S7F).
Similar to our results from the GC model (Figure 6), we attribute
the therapeutic benefit of mIL-11 Mutein in colonic tumors to a
reduction in tumor-associated STAT3 activation and increased
expression of pro-apoptotic BIM (Figures 7D and S7F). Taken
together, these results indicate that inhibition of IL-11 signalingCancer Cell 24, 257–271, August 12, 2013 ª2013 Elsevier Inc. 265
Figure 7. Therapeutic Inhibition of IL-11 Signaling Reduces Tumor Burden in CAC-Challenged WT Mice
(A) CAC-challenged WT mice were treated with mIL-11 Mutein for 4 consecutive weeks commencing on day 46 of the CAC model (refer to Figure S7A). Tumor
burden was scored by serial endoscopy at the indicated time points and is presented as mean ± SEM (nR 4 mice per cohort; *p < 0.05, **p < 0.01).
(B) Colonic tumor burden in individual control and mIL-11 Mutein-treated WT mice at autopsy on day 72. Horizontal lines refer to mean values (nR 9 mice per
cohort; **p < 0.01).
(C) Representative endoscopy images (top row) of distal colonic tumors (arrowhead) and corresponding H&E tissue sections (bottom row) with tumors and
associated inflammatory cells (arrows) in control and mIL-11 Mutein-treated WT mice at day 72 of the CAC protocol. Scale bars: 200 mm.
(D) Representative immunoblot analysis of distal colonic tumor (T) and adjacent nontumor (N) tissue from control andmIL-11Mutein-treatedWTmice collected on
day 72 of the CAC model. ERK1/2 was used as a loading control.
See also Figure S7.
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man CRC.
mIL-11 Mutein Therapy Slows the Growth of Human GI
Cancer Cells in Xenografts
To investigate whether mIL-11 Mutein could also impede the
growth of human GI cancers, we used two representative human
GI cancer derived cell lines, DLD1 and MKN28. DLD1 cells
harbor mutations in APC, PIK3CA, TP53, and KRAS, which are
frequently observed in CRC (Trainer et al., 1988), whereas
MKN28 cells have mutations in TP53, prevalent in GC (Matozaki
et al., 1992). In response to stimulation with recombinant human
IL-11, both cell lines displayed dose-dependent activation of
STAT3 (pTyr-STAT3 staining; Figures 8A and S8A). Because
mIL-11 Mutein cross-reacts with the human IL-11Ra, we
pretreated these cell lines with mIL-11 Mutein and found a
dose-dependent inhibition of hIL-11-mediated STAT3 activation
(Figures 8B and S8B). Given that we observed increased STAT3
activation at the invasive front of human tumors (Figure 1C) and266 Cancer Cell 24, 257–271, August 12, 2013 ª2013 Elsevier Inc.because IL-11 has been implicated in the invasion and
metastasis of epithelial cancer cells (Calon et al., 2012; Lay
et al., 2012), we next examined whether mIL-11 Mutein treat-
ment could inhibit the invasive potential of humanGI cancer cells
in vitro. We found that recombinant hIL-11 promoted cell
migration in a transwell assay and that inhibition of IL-11
signaling by pretreatment with mIL-11 Mutein blocked the inva-
sive capacity of DLD1 andMKN28 cells (Figures 8C and S8C). To
assess whether the growth of human cancer cells in vivo was
susceptible to inhibiting the activity of IL-11 that is produced
by both tumor cells and the surrounding stroma (Figure S8D),
we established subcutaneous xenografts of DLD1 tumor cells
in immune-deficient BALB/c nude mice. Once tumors became
palpable, we treated mice with mIL-11 Mutein for 4 consecutive
weeks. We observed significantly reduced tumor growth in mIL-
11 Mutein-treated animals compared to vehicle-treated con-
trols, resulting in an 50% decrease in tumor mass at autopsy
(Figures 8D and 8E). Immunohistochemical analysis of the
tumors revealed a significant reduction of activated STAT3
Figure 8. Therapeutic Inhibition of IL-11 Signaling Reduces the Growth of Human CRC Cells in Immune-Deficient Mice
(A and B) pTyr-STAT3 in DLD1 cells stimulated with increasing concentrations of recombinant hIL-11 (A) or stimulated with 20 ng/ml of hIL-11 following pre-
treatment with increasing concentrations of mIL-11 Mutein (B). pTyr-STAT3 was determined by flow cytometry. Data in (A) are means ± SEM.
(C) DLD1 cells pretreated with mIL-11Mutein (100 mg/ml) for 60minwere combinedwith recombinant hIL-11 andMatrigel as indicated. Themixture was added to
the top chambers of transwell plates (2 3 105 cells/well) with IL-11-deficient medium in the bottom chambers. Cells that migrated to the bottom chamber were
enumerated 24 hr later. Results represent mean ± SEM (*p < 0.05, **p < 0.01).
(D) BALB/c nudemicewere injected subcutaneously with 53 106 DLD1 cells on contralateral sides.When palpable tumors had formed 3 days later, themicewere
treated three times per week over 24 days with mIL-11 Mutein (10 mg/kg) or a vehicle control. Tumor volumes were calculated from serial caliper measurements,
and the total tumor mass of each individual tumor was determined at autopsy. Horizontal lines refer to mean values. Data are means ± SEM (nR 3 mice per
treatment group; *p < 0.05, **p < 0.01).
(E) Representative photographs of DLD1 xenograft tumors on day 27 (left; scale bars: 11 mm) and corresponding immunohistochemical stains for pTyr-STAT3
(right; scale bars: 100 mm). Insets represent higher magnifications (scale bars: 25 mm).
See also Figure S8.
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role for IL-11-mediated STAT3 signaling in the promotion of GI
cancers. Collectively, our data confirm that therapeutic inhibition
of IL-11 signaling inhibits the progression of human GI tumors.
DISCUSSION
Emerging therapeutic strategies for epithelial cancers have
explored cytokine inhibition as an alternative to pharmacologic
targeting of signal transducing kinases and intracellular
transcription factors. A major focus has been placed on cyto-
kines that suppress tumor cell apoptosis through activation of
nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-kB), including IL-1b and tumor necrosis factor-a (Greten
et al., 2004; Popivanova et al., 2008). Meanwhile, STAT3-acti-
vating cytokines are also attracting therapeutic interest, due to
the prevalence of STAT3 activation in many types of human can-
cers, and the capacity of STAT3 to promote epithelial tumor pro-
gression and to suppress the host’s antitumor immune response(Becker et al., 2004; Bollrath et al., 2009; Yu et al., 2007). In
particular, antibodies that neutralize IL-6 (i.e., siltuximab) or
block IL-6Ra (i.e., tocilizumab) are in clinical trials for ovarian,
prostate, and renal cancers (Guo et al., 2010; Karkera et al.,
2011). Our data argue that despite its overlapping expression
with IL-6, IL-11 is the dominant STAT3-activating cytokine
required for the progression of GI cancers.
Although the contribution of inflammatory cells to GI tumori-
genesis is well established (Rutter et al., 2004), the beneficial
impact of interfering with specific hematopoietic cell types
appears to vary between different types of cancer. Genetic abla-
tion of T and B cells (Boulard et al., 2012), macrophages (Oguma
et al., 2008), mast cells (Gounaris et al., 2007), and components
of the TLR/Myd88-signaling cascade (Rakoff-Nahoum and
Medzhitov, 2007; Tye et al., 2012) reduced GI tumor burden in
mice. Here, we show that the progression of GI tumors is not
influenced by the capacity of hematopoietic cells to respond to
IL-11, but instead requires the response of nonhematopoietic
cells, such as the neoplastic epithelium itself. However, ourCancer Cell 24, 257–271, August 12, 2013 ª2013 Elsevier Inc. 267
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derived cells are a critical source for IL-11, which in turn may
account for the capacity of myeloid cells to promote invasive-
ness of epithelial tumors (Coussens et al., 2000). Consistent
with this, we observed reduced IL-11 expression in NF-kB
signaling-defective myeloid cells, which suppressed invasion
of AOM-induced tumors in Tp53 knockout mice (Schwitalla
et al., 2013).
At this stage, it is not clear if the subtle difference in gene
expression signatures observed between tumors from IL-6-
and IL-11-challenged gp130F/F mice accounts for IL-11-depen-
dent tumor development or whether tumors arise from a distinct
(epithelial) cell population that selectively expresses IL-11Ra, but
not the IL-6Ra. We favor the latter scenario, because the admin-
istration of Hyper-IL-6, a designer cytokine comprised of IL-6
fused to the IL-6Ra cytoplasmic tail, bypassed the requirement
for membrane bound IL-11Ra and increased CAC tumor burden
is an outcome not observed following IL-6 administration (Gri-
vennikov et al., 2009). Consistent with an IL-6 ‘‘trans-signaling’’
mechanism, transgenic mice expressing sgp130-Fc, which
competes with membrane gp130 for binding of IL-6 complexed
to the cleaved IL-6Ra cytosolic domain, are less susceptible to
CAC-induced tumorigenesis (Becker et al., 2004; Matsumoto
et al., 2010). Although ‘‘trans-signaling’’ may also expand the
function of IL-11 to IL-11Ra-deficient tumor cells, cleavage of
the extracellular domain of IL-11Ra has not been observed
in vivo. Given that IL-11 expression is also augmented in
response to oncogenic RAS signaling (Shin et al., 2012), our
results suggest that inhibition of IL-11 signaling may restore
responsiveness to epidermal growth factor receptor (EGFR)
therapy in the broad range of epithelial cancers that are charac-
terized by excessive EGFR expression. This seems plausible,
because cetuximab and other EGFR inhibitors show efficacy
for the treatment of cancers without K-RASmutations (Quesnelle
et al., 2007), while resistance to EGFR inhibition can be over-
come by simultaneous STAT3 suppression (Sen et al., 2012).
We predict that the reliance of the GI tract on IL-11/STAT3
signaling for tumor progression evolved from an intestinal repair
mechanism to provide protection against the continuous inflam-
mation caused by mechanical abrasion of the epithelium, which
is observed in STAT3 signaling-deficient gp130DStat mice (Teb-
butt et al., 2002). By exposing the injured epithelium to platelets,
and other IL-11-producing CD45-positive cells, the mucosal cell
layer can be regenerated from IL-11Ra expressing mucosal
(stem) cells, in part through a STAT3-dependent mechanism.
In the newly emerging epithelium, STAT3 would not only engage
anti-apoptotic and proliferative gene programs, but also simulta-
neously amplify IL-11 expression (Boerma et al., 2007;
Deutscher et al., 2006; Ernst et al., 2008; Gibson et al., 2010;
Orazi et al., 1996). Incidentally, inhibition of IL-11 signaling
increased expression of the pro-apoptotic protein BIM in a
manner akin to that observed in response to therapeutic inhibi-
tion of the STAT3-target VEGF-A (Naik et al., 2011). The func-
tional link between the epithelial repair response and the extent
of local inflammation therefore requires an IL-6 family cytokine
with a tissue specific response like IL-11, rather than the broad
systemic activity elicited by IL-6 that can also exacerbate intes-
tinal inflammation. Indeed, in the absence of overt colitis, the
inflammatory microenvironment associated with sporadic Apc268 Cancer Cell 24, 257–271, August 12, 2013 ª2013 Elsevier Inc.or Tp53mutations confers a growth-promoting advantage to ad-
enomas (Grivennikov et al., 2012; Schwitalla et al., 2013). IL-11
may also facilitate the survival of advanced cancers with multiple
mutations and increase their metastatic capacity (Calon et al.,
2012). The latter effect can be further exacerbated by CAFs,
which are an additional source of IL-11 (Calon et al., 2012) as
well as by tumor hypoxia that is associated with increased IL-
11 production (Onnis et al., 2013).
Direct therapeutic targeting of STAT3 has proven difficult,
although inhibition of upstream activators, including JAK2, has
shown more promise (Hedvat et al., 2009). Unfortunately, sys-
temic inhibition of STAT3 or JAK2 in mice or humans (Ernst
et al., 2008; Santos et al., 2010) is often associated with throm-
bocytopenia. Here, we show that a peptide-based IL-11 antag-
onist is well tolerated with no adverse effects on platelet
numbers, despite the capacity of IL-11 to stimulate megakaryo-
poiesis (Musashi et al., 1991). These observations are consistent
with the phenotype of mice lacking the IL-11 receptor a chain,
which exhibit normal hematopoiesis at steady state and during
response to chemoablative or hemolytic stress (Nandurkar
et al., 1997). However, our results bring into question the clinical
use of recombinant IL-11 for the treatment of thrombocytopenia
in patients undergoing chemotherapy or to reconstitute epithelial
barrier integrity in patients with inflammatory bowel disease
(Cantor et al., 2003; Danese, 2012).
By identifying IL-11 as a functionally dominant inducer of
neoplastic STAT3 activity in the GI epithelium, our studies estab-
lish a molecular entity that can be readily targeted by pharmaco-
logic agents. Therapeutic interference with IL-11 signaling,
therefore, could potentially selectively suppress the STAT3-
associated cancer hallmark capabilities that collectively pro-
mote disease progression of some of the most prevalent
epithelial cancer types in humans. It remains to be established
whether the therapeutic inhibition of IL-11/STAT3 signaling in
turn exposes compensatory pathways in tumor cells that can
be further exploited to induce tumor cell death.
EXPERIMENTAL PROCEDURES
Clinical Material
All human tissueswere obtainedwith informed patient consent and analyzed in
accordance with approval from the ethics committee of the Technical Univer-
sity of Munich, the Peter MaCallum Cancer Center, and the Melbourne Health
Human Ethics Committee (2010.154; 2012.25). Tumor and adjacent normal
(noncancerous) tissues were analyzed.
Mice and Treatments
All animal procedures were approved and conducted in accordance with the
Animal Ethics Committee of the Ludwig Institute for Cancer Research and
the Walter and Eliza Hall Institute, Australia. Mice lacking functional alleles
for IL-11Ra (Il11ra1KO) and IL-6 (Il6KO), homozygous for the gp130(Y757F)
knockin mutation (gp130F/F), or heterozygous for Apc (Apcmin/+) have been
described previously (Ernst et al., 2008; Jenkins et al., 2005; Moser et al.,
1990). The Apcmin/+ compound mutant mice were on a C57Bl/6 genetic back-
ground, whereas others were on a 129/sv x C57Bl/6 genetic background.
Littermate controls were used for comparison when possible. BALB/c nude
animals were purchased from the Australian Research Services. To minimize
variation in gut microflora, all animals were bred in the same room and housed
on the same rack in a specific pathogen-free barrier facility at the Ludwig Insti-
tute for Cancer Research, Australia.
CAC was induced in 129/sv 3 C57Bl/6 mice by intraperitoneal injection of
AOM (10mg/kg; Sigma). Oneweek later, animals were provided drinking water
Cancer Cell
IL-11 Is a Therapeutic Target in GI Cancerad libitum containing 2% DSS (w/v; MP Biomedicals, molecular weight
35,000–50, 000 kDa) for 5 days, followed by 2 weeks of normal drinking water,
which was repeated for two or three cycles as indicated. For CRC, animals
received intraperitoneal injections of AOM (10 mg/kg) once weekly over 6
consecutive weeks. Tumor onset and progression in the distal colon was
monitored by endoscopy as described previously (Becker et al., 2006).
Xenografts were established in 6-week-old nude BALB/c mice by subcu-
taneous injection of 5 3 106 DLD1 cells. Tumor volume was measured every
second day with calipers and calculated using the formula: 0.52*(Tumor
Length*(Tumor Width)^2)/1,000. For therapeutic mIL-11 Mutein treatments,
mice received intraperitoneal injections three times a week over 4 consecutive
weeks with 40 mg/kg mIL-11-Mutein or a PEG-vehicle control (unless other-
wise indicated). The affinity, specificity, and bioactivity of mIL-11-Mutein has
been described previously (Lee et al., 2008).
Statistics
All data are representative of at least two independent experiments. Compar-
isons between values from two groups were performed using Student’s t tests
(two tailed) and multiple groups by ANOVA (Bonferroni post-hoc): * p < 0.05,
** p < 0.01, *** p < 0.001. Additional experimental information is available in
the Supplemental Experimental Procedures.
ACCESSION NUMBER
TheNCBI Gene ExpressionOmnibus repository number for the complete array
data presented in this paper is GSE43800.
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eight figures, and one table and can be found with this article online at
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